[1] CHANG M H, FUNG H B. Besifloxacin:A topical fluoroquinolone for the treatment of bacterial conjunctivitis[J], Clin Ther, 2010, 32(3):454-471. [2] 哈姆斯A E. 喹诺酮羧酸、其衍生物及它们的制备方法和作为抗菌剂的用途. 中国, 101595101A[P]. 2009-12-02. [3] TOMISATO F K, YACHIYO A S, ABIKO H M, et al. Quilonone carboxylic acid derivatives:US, 005447926A[P]. 1995-09-05. [4] 陈再新, 夏正君, 蒋龙, 等. 盐酸贝西沙星的制备方法. 中国, 102659761A[P]. 2012-09-12. [5] WANG Y J, MA Z J. Synthesis of besifloxacin hydrochloride[J]. Hebei Huagong, 2011, 34(7):13-14. 王亚娟, 马志珺. 盐酸贝西沙星的合成[J]. 河北化工, 2011, 34(7):13-14 [6] 王立明, 郭夏, 宋雪梅. 盐酸贝西沙星制备新方法. 中国, 103058992A[P]. 2013-04-24. [7] 田远. 一种盐酸贝西沙星的制备方法. 中国, 104592196A[P]. 2015-05-06. [8] MALHOTRA R, ACKERMAN S, GEARINGER L S. The safety of besifloxacin ophthalmic suspension 0.6% used three times daily for 7 days in the treatment of bacterial conjunctivitis[J]. Drugs R D, 2013, 13(4):243-252. [9] SUN W, GAO X, GUO J, et al. An NMR study on lomustine[J]. Chinese J Magn Reson, 2016, 33(2):353-359. 孙伟, 高翔, 郭娟, 等. 洛莫司汀的1H、13C NMR全归属[J]. 波谱学杂志, 2016, 33(2):353-359. [10] YU D H, KANG W, HAO F, et al. Spectroscopic studies and structural elucidation of cabazitaxel[J]. Chinese J Magn Reson, 2017, 34(2):191-199. 余大海, 康旺, 郝福, 等. 卡巴他赛结构确证的波谱学研究[J]. 波谱学杂志, 2017, 34(2):191-199. [11] YASASWINI P, VIJAYA L M, SAI S M, et al. Development and validation of new RP-HPLC-PDA method for the estimation of besifloxacin hydrochloride in pharmaceutical dosage forms[J]. Indo American Journal of Pharmaceutical Research, 2015, 5(11):3406-3411. |